Discontinued — last reported Q1 '21
Insmed Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount remained flat by 0.0% to $9.72M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 26.0%, from $7.72M to $9.72M. Over 2 years (FY 2023 to FY 2025), Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount shows an upward trend with a 31.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates higher utilization of R&D tax incentives, often correlating with high innovation investment.
Quantifies the reduction in income tax expense attributable to research and development tax credits. This reflects the c...
Highly relevant for technology-heavy or manufacturing firms with significant R&D budgets.
other_income_tax_reconciliation_tax_credits_research| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $22.33M | $30.86M | $38.87M |
| YoY Change | — | +38.2% | +26.0% |